Your browser doesn't support javascript.
loading
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis; Tran, Phu; Gooding, William E; Villaruz, Liza C; Burns, Timothy F; Friedland, David M; Petro, Daniel P; Farooqui, Mariya; Gomez-Garcia, Jose; Gaither-Davis, Autumn; Dacic, Sanja; Argiris, Athanassios; Socinski, Mark A; Stabile, Laura P; Siegfried, Jill M.
Afiliação
  • Tarhini AA; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Rafique I; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Floros T; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Tran P; Department of Medicine, Athens Naval & Veterans Hospital, Athens, Greece.
  • Gooding WE; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Villaruz LC; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Burns TF; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Friedland DM; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Petro DP; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Farooqui M; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Gomez-Garcia J; Department of Medicine, Athens Naval & Veterans Hospital, Athens, Greece.
  • Gaither-Davis A; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Dacic S; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Argiris A; Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.
  • Socinski MA; Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.
  • Stabile LP; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.
  • Siegfried JM; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Cancer ; 123(15): 2936-2944, 2017 Aug 01.
Article em En | MEDLINE | ID: mdl-28472537
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article